-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Raises Price Target to $60

Benzinga·12/22/2025 11:58:54
语音播报
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and raises the price target from $55 to $60.